The possibility and possible aetiology of local prostate cancer (PC) recurrence despite undetectable prostate-specific antigen (PSA) levels are highlighted. A case of a local recurrence 8.5 years after radical prostatectomy for Gleason 3 þ 4 PC is presented. It demonstrates that PC can recur, even after a prolonged period of time (8.5 years), despite undetectable levels (i.e. o0.02 ng/ml) of PSA. In conclusion, the decision to omit digital rectal examination from the follow-up regimens of men with undetectable PSA levels could be justified. In such exceptional cases, however, PC recurrence would be either missed or would only be diagnosed after a considerable delay.
Introduction
The introduction of prostate-specific antigen (PSA) screening in the late 1980s changed the diagnostics and surveillance of prostate cancer (PC) dramatically. 1 Additional to its application as a screening tool, PSA measurement is widely used as a follow-up marker after definite treatment. 2 For decades, radical prostatectomy has been regarded as the therapy of choice for organconfined PC, because of the optimal tumour control, that removal of all prostatic tissue offers. As a result of the procedure, PSA levels should decline to zero within 3 weeks after surgery in those cases with preoperative PSA levels of lower than 15 ng/ml. Detectable PSA levels following surgery are usually indicative for tumour recurrence. Therefore, regular determination of PSA levels is the most reliable and least invasive follow-up method. This generally entails measuring PSA levels at 6-monthly intervals for the first 2 years and either annually or every 2 years thereafter. Whether a digital rectal examination (DRE) should be part of these followup visits was debated in the past but was generally abandoned, because PC recurrence in the absence of rising PSA levels is highly unusual. 3 Although biochemical recurrence generally precedes local or distant metastatic disease by years, we currently report here a case of delayed local tumour recurrence with undetectable PSA levels.
Case
A 69-year-old white male was referred to the urologist because of voiding problems. The patient's medical history was otherwise unremarkable. DRE revealed a nodule that raised the suspicion of capsular penetration, while transrectal ultrasound revealed a hypo-echogenic lesion. Laboratory studies recorded a PSA level of 1.3 ng/ml; a seven-core needle biopsy was subsequently performed, which manifested a prostatic adenocarcinoma (Gleason grade 3 þ 4 ¼ 7) in four cores at the left side. 4 After a negative bone scan, the tumour was staged as cT3a Nx M0. 5 One month after the biopsy, by which time the patient's PSA level had already increased to 2.6 ng/ml, a bilateral pelvic lymphadenectomy and a retropubic radical prostatectomy were performed, and convalescence was uneventful. Histopathological analysis revealed an adenocarcinoma (Gleason grade 3 þ 4 ¼ 7) on the left and right side of the prostate with extensive bilateral capsular penetration and involvement of both seminal vesicles. The surgical margins were negative, as were the pelvic lymph nodes (i.e. pT3c N0 M0). Postoperatively, the patient was fully continent, but suffering from erectile dysfunction. The follow-up regimen consisted of PSA determination every 6 months and incidentally performed DREs.
In August 2005, 101 months after surgery, DRE revealed a distinct nodule in the prostatic bed; a lesion directed biopsy showed recurrence of an adenocarcinoma of the prostate (Gleason grade 3 þ 4 ¼ 7) in all four cores ( Figure 1) . However, the amount of serum PSA present remained at an undetectable level (o0.02 ng/ml) and the patient had no complaints. A CT scan of the abdomen revealed no abnormalities, except for a 2.5 cm Â 2 cm lesion at the prostatic location. Bone scan results were normal, and radiotherapy was administered to the prostatic bed.
Discussion
To date, only four asymptomatic patients have been described as exhibiting local tumour recurrence with an undetectable PSA value after radical prostatectomy. 6, 7 The time period from surgery to pathologically confirmed local recurrence ranged from 10 to 24 months in previous reports; in this case, 8.5 years elapsed between surgery and confirmed local recurrence. Oefelein et al. (1995) 7 described three patients in whom PC recurred despite undetectable PSA levels; two of these displayed local, pathologically confirmed recurrences, with a delay of 10 months and 1.5 years, respectively, between surgery and recurrence. A recently performed review of all men operated on at our institution since the introduction of PSA in 1987 (N ¼ 1118) revealed no adjuvant cases. 8 The last report on this topic was published in 1995. 7 Since then, the sensitivity of PSA assays has improved dramatically. While detection limits of 0.3-0.5 ng/ml were normal a decade ago, nowadays PSA levels of 0.02 ng/ml can be detected; it is entirely possible, therefore, that although levels were low, PSA was not absent in the cases referred to in previously published reports (1989) (1990) (1991) (1992) (1993) (1994) (1995) . 6, 7, 9, 10 This, however, could not be the case in this instance as the PSA assay used at our institution is a Roche Elecsys (Roche, Basel, Switzerland), which has an analytical sensitivity of 0.02 ng/ml.
The aetiology of PC recurrence despite undetectable PSA levels is not clear. Possible explanations for this phenomenon include (1) human or laboratory error, (2) unrecognized hypogonadism, (3) dedifferentiation of the carcinoma and molecular aberrations in the PSA protein. A laboratory error would, of course, be the most logical explanation for the case presented. However in this instance, as was the case in some previously reported cases, the fact that the PSA level was undetectable was confirmed by undertaking a second analysis. It is therefore highly unlikely that this case resulted from error, either human or mechanical.
A normal testosterone level was recorded in this patient, thereby excluding the possibility of hypogonadism as the cause of an undetectable PSA level.
Tumour cells lose their original function as they become more poorly differentiated. It is therefore possible that the patient's PC cells may have been so undifferentiated that PSA production failed. For example, Stege et al.
11 described an inverse relationship between Gleason scores and the PSA content of the malignancy. The Gleason score of our case however was only 3 þ 4, which reflects moderately differentiated disease. Therefore, in this case, as with the case reported by Takayama et al., who considered a patient with a Gleason grade 3 þ 3 (i.e. well-differentiated) recurrence, poor differentiation is unlikely to explain recurrence in the absence of PSA. Moreover, no cases of newly diagnosed prostatic carcinoma have so far been described in conjunction with an absence of PSA. This adds credence to the theory that PC cells cannot be so poorly differentiated that they lose their function.
Conclusion
PSA determination is a highly sensitive technique for monitoring patients after radical prostatectomy. However, in exceptional cases, PC can recur locally despite the absence, or undetectable levels (i.e. o0.02 ng/mL), of PSA. This case report demonstrates that PC can recur in this way even after a prolonged period of time. The very low incidence with which the type of case presented in this paper occurs could be taken to justify the decision to omit DREs from the follow-up regimens of men with undetectable PSA levels. However, the fact remains that, in such exceptional cases, PC recurrence would be either missed or would only be diagnosed after a considerable delay. Figure 1 Needle biopsy of the prostatic bed after radical prostatectomy manifests localization of adenocarcinoma (Gleason score 3 þ 4 ¼ 7). Original magnification, Â 100.
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